Plumbagin enhances TRAIL-mediated apoptosis through up-regulation of death receptor in human melanoma A375 cells

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 30, Issue 4, 2010, Pages 458-463

  Li, Jiawen ^a   Shen, Qin ^a   Peng, Rui ^b   Chen, Rongyi ^a   Jiang, Ping ^a   Li, Yanqiu ^a   Zhang, Li ^a   Lu, Jingjing ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUBEI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

apoptosis; DR4; DR5; melanoma; plumbagin; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; CASP3 PROTEIN, HUMAN; CASP8 PROTEIN, HUMAN; CASPASE 3; CASPASE 8; NAPHTHOQUINONE; PLUMBAGIN; TNFRSF10A PROTEIN, HUMAN; TNFRSF10B PROTEIN, HUMAN; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; DRUG EFFECT; HUMAN; MELANOMA; METABOLISM; PATHOLOGY; SKIN TUMOR; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CASPASE 3; CASPASE 8; CELL LINE, TUMOR; HUMANS; MELANOMA; NAPHTHOQUINONES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SKIN NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

EID: 77956246507     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-010-0449-x     Document Type: Article

References (27)

1. Y.J. Hsieh L.C. Lin T.H. Tsai 2005 Determination and identification of plumbagin from the roots of Plumbago zeylanica L. by liquid chromatography with tandem mass spectrometry Chromatogr A 1083 1-2 141 145 10.1016/j.chroma.2005.06. 030 1:CAS:528:DC%2BD2MXlvVemtrc%3D
2. J.S. Mossa F.S. El-Feraly I. Muhammad 2004 Antimycobacterial constituents from Juniperus procera, Ferula communis and Plumbago zeylanica and their in vitro synergistic activity with isonicotinic acid hydrazide Phytother Res 18 11 934 937 10.1002/ptr.1420 1:CAS:528:DC%2BD2MXotF2gug%3D%3D 15597311
3. P. Srinivas G. Gopinath A. Banerji, et al. 2004 Plumbagin induces reactive oxygen species, which mediate apoptosis in human cervical cancer cells Mol Carcinog 40 4 201 211 10.1002/mc.20031 1:CAS:528:DC%2BD2cXmvFOhtbY%3D 15264212
4. Y. Ding Z.J. Chen S. Liu, et al. 2005 Inhibition of Nox-4 activity by plumbagin, a plant-derived bioactive naphthoquinone Pharm Pharmacol 57 1 111 116 1:CAS:528:DC%2BD2MXlsVSisw%3D%3D
5. Y.L. Hsu C.Y. Cho P.L. Kuo, et al. 2006 Plumbagin (5-hydroxy-2-methyl-1, 4-naphthoquinone) induces apoptosis and cell cycle arrest in A549 cells through p53 accumulation via c-Jun NH2-terminal kinase-mediated phosphorylation at serine 15 in vitro and in vivo Pharmacol Exp Ther 318 2 484 894 10.1124/jpet.105.098863 1:CAS:528:DC%2BD28XnslOls7w%3D
6. P.L. Kuo Y.L. Hsu C.Y. Cho, et al. 2006 Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells Mol Cancer Ther 5 12 3209 3221 10.1158/1535-7163.MCT-06-0478 1:CAS:528:DC%2BD28XhtlagsbvF 17172425
7. A.A. Powolny S.V. Sinqh 2008 Plumbagin-induced apoptosis in human prostate cancer cells is associated with modulation of cellular redox status and generation of reactive oxygen species Pharm Res 25 9 2171 2180 10.1007/s11095-008-9533-3 1:CAS:528:DC%2BD1cXps1ajtrg%3D 18213451
8. S.K. Sandur H. Ichikawa G. Sethi, et al. 2006 Plumbagin (5-hydroxy-2-methyl-1,4-aphthoquinone) suppresses NF-kappaB activation and NF-kappaBregulated gene products through modulation of p65 and IkappaBalpha kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents Biol Chem 281 25 17 023 17033 1:CAS:528: DC%2BD28XlvVGks7c%3D
9. A. Kawiak J. Piosik G. Stasilojc, et al. 2007 Induction of apoptosis by plumbagin through reactive oxygen species-mediated inhibition of topoisomerase II Toxicol Appl Pharmacol 223 3 267 276 10.1016/j.taap.2007.05.018 1:CAS:528:DC%2BD2sXhtVWhsbnI 17618663
10. S. Nagata 1997 Apoptosis by death factor Cell 88 3 55 65 10.1016/S0092-8674(00)81874-7
11. A. Ashkenazi V.M. Dixit 1998 Death receptors: signling and modulation Science 281 5381 1305 1308 10.1126/science.281.5381.1305 1:CAS:528: DyaK1cXlvVegsL0%3D 9721089
12. H. Walczak P.H. Krammer 2000 The CD95(APO-1/Fas) and the TRAIL(APO-2L) apoptosis systems EXP CELL Res 256 1 58 66 10.1006/excr.2000.4840 1:CAS:528:DC%2BD3cXitVajsb4%3D 10739652
13. H. Walczak R.E. Miller K. Ariail, et al. 1999 Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo Nat Med 5 2 157 163 10.1038/5517 1:CAS:528:DyaK1MXntlSrug%3D%3D 9930862
14. A. Ashkenazi R.C. Pai S. Fong, et al. 1999 Safety and antitumor activity of recombinant soluble Apo2 ligand Clin Invest 104 2 155 162 10.1172/JCI6926 1:CAS:528:DyaK1MXkslSmsbw%3D
15. D.T. Nguyen X.D. Zhang P. Hersey 2001 Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis Clin Cancer Res 7 3Supple 966s 973s 1:CAS:528:DC%2BD3MXjtFWktr0%3D 11300498
16. X.D. Zhang J.J. Wu S.K. Gillespie, et al. 2006 Human melamoma cells selected for resistant to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnernable to non-apoptosis cell death induced by cisplatin Clin Cancer Res 12 4 1355 1364 10.1158/1078-0432.CCR-05-2084 1:CAS:528:DC%2BD28XhsFalur0%3D 16489094
17. J.J. Wu X.D. Zhang S. Gillespie, et al. 2005 Selection for TRAIL resistance results in melanoma cells with high prolifeative potential FEBS Lett 579 9 1940 1944 10.1016/j.febslet.2005.02.041 1:CAS:528:DC%2BD2MXisFGqu7s%3D 15792800
18. B.M. Kurbanov C.C. Geilen L.F. Fecker, et al. 2005 Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) Invest Dermatol 125 5 1010 1019 10.1111/j.0022-202X.2005.23900.x 1:CAS:528:DC%2BD2MXht1GrtrrK
19. B.M. Kurbanov L.F. Fecker C.C. Geilen, et al. 2007 Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptosis proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4 Oncogene 26 23 3364 3377 10.1038/sj.onc.1210134 1:CAS:528:DC%2BD2sXltlejsrs%3D 17160022
20. S. Shankar X. Chen R.K. Srivastava 2005 Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo Prostate 62 2 165 186 10.1002/pros.20126 1:CAS:528:DC%2BD2MXht12jtLo%3D 15389801
21. S. Shankar T.R. Singh R.K. Srivastava 2004 Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms Prostate 61 1 35 49 10.1002/pros.20069 1:CAS:528:DC%2BD2cXnvVCnsLo%3D 15287092
22. T.R. Singh S. Shankar X. Chen, et al. 2003 Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo Cancer Res 63 17 5390 5400 1:CAS:528:DC%2BD3sXntlekurg%3D 14500373
23. T.R. Singh S. Shankar R.K. Srivastava 2005 HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma Oncogene 24 29 4609 4623 10.1038/sj.onc.1208585 1:CAS:528:DC%2BD2MXlvVGhsbg%3D 15897906
24. S. Shankar T.R. Singh X. Chen, et al. 2004 The sequential treatment with ionizing radiation followed by TRAIL/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice Int J Oncol 24 5 1133 1140 1:CAS:528:DC%2BD2cXjvVGnsr0%3D 15067334
25. S. Shankar T.R. Singh T.E. Fandy, et al. 2005 Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: Involvement of both death receptor and mitochondrial pathways Int J Mol Med 16 6 1125 1138 1:CAS:528:DC%2BD2MXhtlWrt7zE 16273296
26. L. Zhuang C.S. Less R.A. Scolyer, et al. 2006 Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-induced ligand Hum Pathol 37 10 1286 1294 10.1016/j.humpath.2006.04.026 1:CAS:528:DC%2BD28XpvV2lsrY%3D 16949935
27. C.M. Van Geelen E.G. de Vries S. de Jong 2004 Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy Drug Resist Updat 7 6 345 358 10.1016/j.drup.2004.11. 002 15790545